Elevated cholesterol levels, especially low lipoprotein cholesterol (LDL-C), leads to atherosclerosis—which may increase the risk of heart attack, stroke, and peripheral artery disease. Statins are common medications that can help lower cholesterol levels. However, myopathy can be a serious side effect that prevents patients from taking statins and significantly decreases overall quality of life. Described herein are dosage forms containing select combinations of natural herbal extracts and phytonutrients having the surprising ability to lower LDL-C levels in amounts comparable to statin drugs without noted side effects such as myopathy.

The present invention relates to a composition comprising a combination of a (halogenoacetamido)benzoate, a flavonol and a terpene, and, as example, relates to a composition comprising the combination of ethyl 3-(2-chloroacetamido)benzoate, dihydroquercetin and bisabolol. Said composition is for use in the treatment of leishmaniasis, especially cutaneous or mucosal leishmaniasis, the composition being applied topically for concomitantly treating both parasitic infection and skin inflammation of the infected area induced by leishmaniasis.

The present invention relates to a composition comprising a combination of a (halogenoacetamido)benzoate, a flavonol and a terpene, and, as example, relates to a composition comprising the combination of ethyl 3-(2-chloroacetamido)benzoate, dihydroquercetin and bisabolol. Said composition is for use in the treatment of leishmaniasis, especially cutaneous or mucosal leishmaniasis, the composition being applied topically for concomitantly treating both parasitic infection and skin inflammation of the infected area induced by leishmaniasis.

Pharmaceutical compositions having a carrier and a pharmaceutically effective amount of at least one modulator of an activity which is responsive to modulation by at least one selected from the group consisting of anadamide, N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine and is responsive to modulation by 2-arachidonoylglycerol (2-AG) to an extent that is no greater than that provided by at least one of anadamide, OEA, PEA and seretonine at the same molar dose, wherein the composition is devoid of a sole modulator selected from the group consisting of cannabidiol (CBD), anadamide N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine, for use in treating a condition characterized by anandamide deficiency or a symptom thereof, pharmaceutical preparations and kits including the composition, and methods of use thereof.

Pharmaceutical compositions having a carrier and a pharmaceutically effective amount of at least one modulator of an activity which is responsive to modulation by at least one selected from the group consisting of anadamide, N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine and is responsive to modulation by 2-arachidonoylglycerol (2-AG) to an extent that is no greater than that provided by at least one of anadamide, OEA, PEA and seretonine at the same molar dose, wherein the composition is devoid of a sole modulator selected from the group consisting of cannabidiol (CBD), anadamide N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine, for use in treating a condition characterized by anandamide deficiency or a symptom thereof, pharmaceutical preparations and kits including the composition, and methods of use thereof.

Pharmaceutical compositions having a carrier and a pharmaceutically effective amount of at least one modulator of an activity which is responsive to modulation by at least one selected from the group consisting of anadamide, N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine and is responsive to modulation by 2-arachidonoylglycerol (2-AG) to an extent that is no greater than that provided by at least one of anadamide, OEA, PEA and seretonine at the same molar dose, wherein the composition is devoid of a sole modulator selected from the group consisting of cannabidiol (CBD), anadamide N-Oleoylethanolamine (OEA), N-palmitoylethanolamind (PEA) and seretonine, for use in treating a condition characterized by anandamide deficiency or a symptom thereof, pharmaceutical preparations and kits including the composition, and methods of use thereof.

A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.

A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.

The invention relates to a composition for the treatment of male infertility. The invention is characterized by a composition comprising L-carnitine and/or acetyl-L-carnitine or prodrugs thereof for the treatment of infertility in men with a sperm concentration of less than 5 million spermatozoa per milliliter.

The invention relates to a composition for the treatment of male infertility. The invention is characterized by a composition comprising L-carnitine and/or acetyl-L-carnitine or prodrugs thereof for the treatment of infertility in men with a sperm concentration of less than 5 million spermatozoa per milliliter.